PROVENGE® (sipuleucel-T)

Dendreon Pharmaceuticals Partners with Grant Hill to Help Men Start Strong with Advanced Prostate Cancer

Retrieved on: 
Wednesday, November 17, 2021
Biotechnology, Sports, Pharmaceutical, Men, Oncology, Health, Consumer, Basketball, the PROCEED Registry, Prostate Cancer in African American Men, PROVENGE® (sipuleucel-T), Dendreon, THE PROCEED REGISTRY, PROSTATE CANCER IN AFRICAN AMERICAN MEN, PROVENGE® (SIPULEUCEL-T), DENDREON

Prostate cancer is a risk for all men, but it disproportionately impacts African American men.

Key Points: 
  • Prostate cancer is a risk for all men, but it disproportionately impacts African American men.
  • Men with metastatic castration-resistant prostate cancer (mCRPC) were randomly assigned to receive PROVENGE or not receive PROVENGE.
  • However, African American men treated with an immunotherapy called PROVENGE may have longer overall survival compared with Caucasian men.
  • For more information, visit startstrong.us to learn about appropriate treatment options for advanced prostate cancer.

Real-World Evidence Shows Adding PROVENGE® (sipuleucel-T) to Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival by 14.5 Months

Retrieved on: 
Wednesday, October 14, 2020
Stem cells, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Other Health, Cancer vaccines, Clinical medicine, Medicine, Anatomy, Sipuleucel-T, Prostate cancer, Immunotherapy, Prostate, Dendreon, Neuvenge, PROVENGE® (sipuleucel-T), Dendreon

PROVENGE continues to deliver on its promise of helping men with advanced prostate cancer live longer and should be considered when making treatment decisions in daily clinical practice.

Key Points: 
  • PROVENGE continues to deliver on its promise of helping men with advanced prostate cancer live longer and should be considered when making treatment decisions in daily clinical practice.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.
  • A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.

Study Shows African American Men with Advanced Prostate Cancer Treated with PROVENGE® (sipuleucel-T) Live Longer than Caucasian Men

Retrieved on: 
Thursday, March 12, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Prostate cancer, Cancer, Clinical medicine, Neoplasms, MCRPC, Sipuleucel-T, the PROCEED Registry, Prostate Cancer in African American Men, PROVENGE® (sipuleucel-T), Dendreon

These findings add to the growing body of published clinical evidence that PROVENGE extends life in men with mCRPC and underscore its added effectiveness in African American men, said Bruce A.

Key Points: 
  • These findings add to the growing body of published clinical evidence that PROVENGE extends life in men with mCRPC and underscore its added effectiveness in African American men, said Bruce A.
  • No other prostate cancer treatment has shown this level of added benefit in African American men with mCRPC, so these findings are exciting.
  • More than 30,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010.
  • Median OS in men with a baseline PSA >29.48 ng/mL was 22.7 months for African American men and 17.6 months for Caucasian men.

Real-World Study of 6,000+ Medicare Patients with Advanced Prostate Cancer Shows Adding PROVENGE® (sipuleucel-T) to Treatment Regimen Reduced Risk of Death by 45%

Retrieved on: 
Thursday, February 13, 2020
FDA, MEN, Clinical trials, Biotechnology, Health, Consumer, Pharmaceutical, General Health, Oncology, Cancer vaccines, Prostate cancer, Sipuleucel-T, Thierry Breton, PROVENGE® (sipuleucel-T), Dendreon

Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p

Key Points: 
  • Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p
  • More than 150 variations of mCRPC treatment sequences were identified in the analysis, underscoring the importance of developing a structured approach to managing mCRPC patients.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Largest Real-World Study of Immunotherapy Shows Men with Advanced Prostate Cancer with Low PSA had a Median Survival of Nearly Four Years after Treatment with PROVENGE® (sipuleucel-T)

Retrieved on: 
Wednesday, September 4, 2019
Biotechnology, Pharmaceutical, Oncology, MEN, Health, Consumer, Cancer vaccines, Clinical medicine, Cancer, Medicine, Prostate cancer, Sipuleucel-T, MCRPC, Immunotherapy, Neuvenge, Dendreon, the PROCEED Registry, PROVENGE® (sipuleucel-T), Dendreon

Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN).

Key Points: 
  • Of those, 95% were treated with PROVENGE as first-line therapy for mCRPC as recommended by the National Comprehensive Cancer Network (NCCN).
  • Median baseline PSA levels at mCRPC diagnosis have declined steadily since the approval of PROVENGE in 2010, said Bruce A.
  • PROVENGE is the only FDA-approved immunotherapy made from a patients own immune cells for the treatment of prostate cancer.
  • PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.